About FAD-linked sulfhydryl oxidase ALR
FAD-linked sulfhydryl oxidase ALR (GFER) is a protein
from Homo sapiens identified by UniProt accession
P55789, 205 residues long.
MolForge cross-references it against 0 known binders and
138 disease associations.
Target properties
| Protein name | FAD-linked sulfhydryl oxidase ALR |
| UniProt accession | P55789 |
| Gene | GFER |
| Organism | Homo sapiens |
| Length | 205 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (11)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (138)
Diseases linked to this target (Open Targets).
- Congenital cataract - progressive muscular hypotonia - hearing loss - developmental delay · score 0.75
- congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome · score 0.70
- neurodegenerative disease · score 0.55
- genetic disorder · score 0.47
- mitochondrial disease · score 0.42
- Intellectual disability · score 0.37
- lysosomal storage disease · score 0.25
- Red cell distribution width · score 0.18
- hypertension · score 0.11
- cardiovascular disease · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P55789-F1 | alphafold | PREDICTED | 76.86 | — |
Amino-acid sequence (205 residues)
MAAPGERGRF HGGNLFFLPG GARSEMMDDL ATDARGRGAG RRDAAASAST PAQAPTSDSP VAEDASRRRP CRACVDFKTW MRTQQKRDTK FREDCPPDRE ELGRHSWAVL HTLAAYYPDL PTPEQQQDMA QFIHLFSKFY PCEECAEDLR KRLCRNHPDT RTRACFTQWL CHLHNEVNRK LGKPDFDCSK VDERWRDGWK DGSCD
Explore FAD-linked sulfhydryl oxidase ALR with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets